Administration of ndSTAT1-TMD to psoriasis- and IBD-induced mice effectively attenuated the clinical symptoms of diseases and delayed disease progression by restoring the disrupted imbalance of CD4+ effector T cells in the secondary lymph organs. Here, CD4 is linked to inflammatory bowel disease.